SynthesisCurrent osteoporosis reports2025
Headline: Fracture Risk in Type 2 Diabetes: Systematic Review of Cardiovascular Outcome Trials with Glucagon Like Peptide Receptor Agonists.
Synthesis in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Disease and Fracture Risk in People with Type 2 Diabetes: A Nationwide Matched Case-Control Study.Calcified tissue international · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis systematic review examined the available evidence on fracture risk in people with type 2 diabetes (T2D) using cardiovascular outcome trials with glucagon-like peptide-1 receptor agonist (GLP-1RA). RECENT
findingsA systematic Literature search identified 797 records, of which 643 remained after duplicate removal. Following screening, 20 studies met the criteria for inclusion. Although GLP-1 RAs have demonstrated well-established benefits in glycaemic control, weight reduction, and cardiovascular protection, their impact on bone health remains incompletely understood. Preclinical studies suggest potential bone-protective effects, including increased bone mass, improved microarchitecture, and reduced bone resorption. However, evidence from human studies has been inconsistent. While some findings indicate a possible reduction in fracture risk with long-term GLP-1 RA therapy, further research is needed to clarify their role in bone metabolism and fracture prevention among people with T2D, particularly within the context of cardiovascular outcome trials.
Indexed as
Identifiers
41026248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.